FDAnews
www.fdanews.com/articles/61450-amorfix-life-sciences-and-biogen-idec-to-collaborate-on-research-for-als-disease

AMORFIX LIFE SCIENCES AND BIOGEN IDEC TO COLLABORATE ON RESEARCH FOR ALS DISEASE

August 4, 2006

Amorfix Life Sciences Ltd., an emerging Canadian theranostics company, announced today that it has entered into a research and investment agreement with Biogen Idec of Cambridge, Massachusetts, which includes an option to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against the neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS). Amorfix will conduct a planned research program with operational support and investment from Biogen Idec.

CNW Group (http://www.newswire.ca/en/releases/archive/August2006/03/c3378.html)